Drug Trial Radar · NCT07370584
A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Feb 4, 2026
Primary completion
Apr 1, 2026
Study completion May 13, 2026
Sponsor
- Lead sponsor
- iVeena Delivery Systems, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Lexitas Pharma Services, Inc.
- First posted
- Jan 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this trial is to determine the safety of IVMED-85 eye drops in healthy adult subjects. Participants will be assigned to either the active or vehicle eyedrop group. The participants will receive eye drops twice daily for 6 weeks. Participants will not know which eyedrop they are taking.
Conditions
- Safety Study
Interventions
IVMED-85 ophthalmic solutionDrug
IVMED-85 ophthalmic solution (0.20 mg/mL), administer twice a day (morning and evening) in both eyes
Vehicle Ophthalmic SolutionDrug
Vehicle ophthalmic solution, administer twice a day (morning and evening) in both eyes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual acuityTime frame: From enrollment to the end of treatment at 6 weeks
- Change in eye assessmentsTime frame: From enrollment to the end of treatment at 6 weeks
- Punctal stenosis or Bloody dischargeTime frame: From enrollment to the end of treatment at 6 weeks
- Change in ocular assessmentsTime frame: From enrollment to the end of treatment at 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Total Eye Care, P.A.
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.